RecruitingPhase 2NCT06253117

Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Alabama at Birmingham
Intervention
Pirfenidone(drug)
Enrollment
60 enrolled
Eligibility
18-85 years · All sexes
Timeline
2024 – 2028

Study locations (2)

Collaborators

Congressionally Directed Medical Research Programs

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06253117 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease →

← Back to all trials